{{Rsnum
|rsid=5945572
|Chromosome=X
|position=51486831
|Orientation=plus
|GMAF=0.2382
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 32.3 | 20.0 | 47.7
| HCB | 0.8 | 3.8 | 95.5
| JPT | 4.5 | 11.4 | 84.1
| YRI | 25.4 | 20.6 | 54.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.8 | 3.8 | 95.5
| CHD | 5.7 | 4.7 | 89.6
| GIH | 0.0 | 0.0 | 0.0
| LWK | 12.4 | 18.1 | 69.5
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}Associated with [[prostate cancer]] {{PMID|18264098|OA=1
}}{{PMID|18774487}}

{{GWAS Summary
|SNP=rs5945572
|PubMedID=18264098
|Condition=Prostate cancer
|Gene=NUDT10, NUDT11, LOC340602, GSPT2, MAGED1
|Risk Allele=A
|pValue=4.00E-013
|OR=1.23
|95CI=1.16-1.30
|OA=1
}}

{{PMID Auto
|PMID=19549809
|Title=Fine-Mapping and Family-Based Association Analyses of Prostate Cancer Risk Variants at Xp11
|OA=1
}}

{{omim
|desc=PROSTATE CANCER
|id=176807
|rsnum=5945572
}}

{{omim
|desc=PROSTATE CANCER, HEREDITARY, X-LINKED 2; HPCX2
|id=300704
|rsnum=5945572
}}
{{PMID Auto
|PMID=19902474
|Title=Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans
}}

{{PharmGKB
|RSID=rs5945572
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:18264098; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer (Initial Sample Size: 1,854 cases, 21,372 controls; Replication Sample Size: 8,239 cases, 7,590 controls; Risk Allele: rs5945572-A).
|Drugs=
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356750
}}

{{PMID Auto
|PMID=20651075
|Title=Prostate Cancer Susceptibility Variants Confer Increased Risk of Disease Progression
|OA=1
}}

{{PharmGKB
|RSID=rs5945572
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:18264098
|Annotation=This SNP on Xp11.22 was shown to be associated with prostate cancer in a genome-wide SNP association study on over 23,000 Icelanders, followed by a replication study including over 15,500 individuals from Europe and the United States.
|Drugs=
|Drug Classes=
|Diseases=Prostatic Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA161925609
}}

{{PMID|18708398|OA=1
}} Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium.

{{PMID|19318432|OA=1
}} Generalizability of associations from prostate cancer genome-wide association studies in multiple populations.

{{PMID|19336566|OA=1
}} Replication of the 10q11 and Xp11 prostate cancer risk variants: results from a Utah pedigree-based study.

{{PMID|20690139}} Meta-analysis of genome-wide and replication association studies on prostate cancer.

{{PMID|21071540|OA=1
}} Validation of genome-wide prostate cancer associations in men of African descent.

{{PMID|21390317|OA=1
}} Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers--results from BPC3.

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs5945572
|overall_frequency_n=63
|overall_frequency_d=92
|overall_frequency=0.684783
|n_genomes=43
|n_genomes_annotated=0
|n_haplomes=82
|n_articles=1
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{PMID Auto
|PMID=23159463
|Title=Genetic sequence variants are associated with severity of lower urinary tract symptoms and prostate cancer susceptibility.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}